Quality indicators (%)	Expected performance	Performance
		2015	2016	2017	2018	2019
Newborn health education	>95.0%	90.92%	93.0%	93.9%	100%	100%
Unsatisfactory DBS samples#	<0.5%	0.47%	0.45%	0.44%	0.43%	0.38%
Cards missing essential information#	<0.1%	0.35%	0.27%	0.16%	0.09%	0.05%
DBS samples with acceptable transport time#	>95.0%	92.9%	94.2%	97.9%	100%	100%
Test reports with an acceptable time from specimen receipt to results reporting#	>95.0%	94.8%	95.2%	97.4%	98.4%	98.7%
Test items running IQC	100%	100%	100%	100%	100%	100%
Unsatisfactory testing results in IQC†	<1.0%	1.1%	0.8%	0.6%	0.3%	0.0%
Newborns with positive results in primary screening†	<5.0%	3.6%	3.1%	2.2%	2.1%	2.0%
Newborns recalled after positive primary screening#	100%	88.79%	91.1%	93.9%	96.9%	99.6%
Newborns with positive results in secondary screening†	<1.0%	1.6%	1.1%	0.82%	0.78%	0.72%
Newborns recalled after positive secondary screening#	100%	100%	100%	100%	100%	100%
Newborns with false-negative screening results	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Positive predictive value	>20.0%	14.2%	14.6%	15.0%	15.2%	15.4%
Annual disease incidence‡	–	–	–	–	–	–
Newborns that received NBS	>95.0%	86.8%	90.8%	95.8%	98.0%	98.6%
Newborns lost to follow-up	<0.1%	0.22%	0.20%	0.17%	0.13%	0.08%

^#Quality indicators were evaluated monthly. Monthly data from January 2015 to December 2019 were converted to annual metrics for analysis.

^†Quality indicators were evaluated monthly. Four screening items were included: thyroid stimulating hormone, phenylalanine, glucose-6-phosphate dehydrogenase, and 17α-hydroxyprogesterone. Monthly quality improvement data were converted to annual metrics for analysis.

^‡The annual disease incidence of each screening item was variable; data were not shown.

IQC, internal quality control; DBS, dried blood spot; NBS, newborn screening.